Background Barriers to cancer clinical trial participation have been the subject of frequent
study, but the rate of trial participation has not changed substantially over time. Studies often …

Minority US populations are underrepresented in cancer clinical trials. This review appraises
the impact of the disparity in clinical trial participation by minority patients in the current era …

This article examines the consequences and causes of low enrollment of Black patients in
clinical trials. We develop a simple model of similarity-based extrapolation that predicts that …

Importance Industry involvement is prominent in influential clinical trials, and commitments to
transparency of trials are highly variable. Objective To evaluate the modes of industry …

Background Funders encourage lay‐volunteer inclusion in research. There are controversy
and resistance, given concerns of role confusion, exploratory methods, and limited evidence …

The ability to identify medical reversals and other low-value medical practices is an essential
prerequisite for efforts to reduce spending on such practices. Through an analysis of more …

Background: Although there are considerable racial and ethnic disparities in prostate cancer
incidence and mortality in the United States and globally, clinical trials often do not reflect …

Patients from historically under-represented racial and ethnic groups are enrolled in cancer
clinical trials at disproportionately low rates in the USA,–. As these patients often have …

Abstract Funding agencies in North America and Europe are recognizing the importance of
the integration of sex differences into basic and clinical research. Although these mandates …

Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity:
retrospective cross sectional study - PMC Back to Top Skip to main content NIH NLM Logo …